References
- Hodge KK, Mcneal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71–75
- Stricker HJ, Ruddock LJ, Wan J, Belville WD. Detection of nonpalpable prostate cancer. A mathematical and laboratory model. Br J Urol. 1993;71:43–46
- Eskiçorapçı SY, Baydar DE, Akbal C, et al. An extended 10 core transrectal ultrsonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol. 2004;45:444–449
- Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method diagnosing carcinoma of the prostate. J Urol. 1997;157:199–203
- Chen ME, Troncoso P, Tang K, Babaian RJ, Johnston D. Comparison of prostate biopsy schemes by computer simulation. Urology. 1999;53:951–960
- Elabbaday AA, Khedr MM. Extended 12 core prostate biopsy increase both te detection of prostate cancer and the accuracy of Gleason score. Eur Urol. 2006;49:49–53
- Nakai S, Shinzato T, Nagura Y, et al. Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial. 2004;8(1):3–32
- Wada Y, Nakanishi J, Takahashi W, et al. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study. BJU Int. 2006;98:794–797
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266
- Gore JL, Shariat SF, Miles BJ, et al. Optimal Combination of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165:1554–1559
- Presti JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000;163:163–166
- Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93–99
- Palestini M, Lucandri G, Sterpetti A, Izzo L, Orefici F, Cavallaro A. Cancer surveillance in patients receiving long-term hemodialysis. Anticancer Res. 2002;22:1305–1310
- Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol. 2002;33:121–126
- Chen CJ, Heldt JP, Anderson KM, et al. Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease. J Urol. 2012;187(6):2061–2065
- Vamvakas S, Bahner U, Heidland A. Cancer in end stage renal disease: potential factors involved. Am J Nephrol. 1998;18:89–95
- Kurahashi T, Miyake H, Shinozaki M, et al. Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis. Int Urol Nephrol. 2008;40:345–349
- Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol. 2009;20:1341–1350
- Bauer JJ, Zeng J, Weir J, et al. Three-dimensional computer-simulated prostate models: lateral prostate biopsy cores increase the detection rate of prostate cancer. Urology. 1999;53:961–967
- Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000;163:152–157
- Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605–1612
- Stamey TA. Making the most out of six systematic sextant biopsy. Urology. 1995;45:71–74